Nanexa AB's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 278.25.
Nanexa AB's Days Inventory for the
three
months ended in Mar. 2026 was .
Nanexa AB's Days Payable for the
three
months ended in Mar. 2026 was .
Therefore, Nanexa AB's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 278.25.
Nanexa AB (FRA:40M) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Nanexa AB Cash Conversion Cycle Related Terms
Nanexa AB Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Nanexa AB's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:40M vs ZTS, UTHR: Cash Conversion Cycle Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Nanexa AB's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanexa AB Cash Conversion Cycle vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nanexa AB's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Nanexa AB's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Nanexa AB's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanexa AB (FRA:40M) has a Cash Conversion Cycle of 278.25 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Nanexa AB and its competitors.
Is Nanexa AB's Cash Conversion Cycle too high?
Nanexa AB's current Cash Conversion Cycle is 278.25. The Drug Manufacturers industry median Cash Conversion Cycle is 145.82. Nanexa AB's value of 278.25 is 90.8% above this industry median. Overall, Nanexa AB has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nanexa AB's Cash Conversion Cycle compare to ZTS and UTHR?
Nanexa AB's Cash Conversion Cycle of 278.25 can be compared against companies in the Drug Manufacturers industry. The industry median Cash Conversion Cycle is 145.82. Nanexa AB's value of 278.25 is 90.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Drug Manufacturers company?
The median Cash Conversion Cycle among Drug Manufacturers companies is 145.82, based on 949 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanexa AB's current Cash Conversion Cycle of 278.25 is 90.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Nanexa AB and its competitors. For the Drug Manufacturers industry, the median Cash Conversion Cycle is 145.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanexa AB's current Cash Conversion Cycle is 278.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanexa AB stock overvalued right now?
Based on GuruFocus' analysis, Nanexa AB (FRA:40M) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.17, compared to a current price of €0.30 — trading 77.6% above its estimated fair value. The current Cash Conversion Cycle is 278.25 and 90.8% above the Drug Manufacturers industry median of 145.82. Nanexa AB's overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Nanexa AB (FRA:40M), the current Cash Conversion Cycle is 278.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanexa AB (FRA:40M) Overvalued in 2026?
Based on GuruFocus' analysis, Nanexa AB stock appears to be overvalued.
The current stock price of €0.30 is trading 77.6% above its estimated GF Value™ of €0.17.
GuruFocus considers Nanexa AB to be Significantly Overvalued.
Key valuation signals for FRA:40M:
Cash Conversion Cycle: 278.25
GF Value™: €0.17 vs. price of €0.30 (77.6% above fair value)
Industry Position: 90.8% above the Drug Manufacturers median
No single metric tells the full story. See the FRA:40M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanexa AB is a pharmaceutical company developing injectable drug products based on the proprietary drug delivery system PharmaShell - the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. The company develops its products and also has collaboration agreements with several pharma companies, among others AstraZeneca. Geographically, the company derives maximum revenue from Nordic countries, while it also has its presence in Europe (excluding the Nordic countries), North America, and Asia.
48GF Score
Get the complete analysis for FRA:40M
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:40M has been successfully added to your 
